Prevention · 9 min read · Updated March 2026

Rapamycin for Cancer Prevention: The Most Compelling Biology With the Biggest Evidence Gap

mTOR is hyperactivated in 70% of cancers. Rapalogs are FDA-approved cancer treatments. Transplant patients on rapamycin get 40-60% fewer cancers. But no prevention RCTs exist yet.

🔶 Grade C: Early / Limited

The Bottom Line

Rapamycin (sirolimus) is an mTOR inhibitor with the most compelling biological rationale for cancer prevention of any prescription drug. mTOR is the master growth switch that cancer cells hijack to proliferate. Rapamycin and its analogs (everolimus, temsirolimus) are already FDA-approved cancer treatments for renal cell carcinoma and certain breast cancers. The longevity community uses low-dose rapamycin (3-6mg weekly) off-label for healthspan extension, and the cancer prevention angle is central to that rationale. However, no RCTs have tested low-dose rapamycin specifically for cancer prevention in healthy people. The evidence gap between "compelling biology" and "proven prevention" remains wide.

How mTOR Drives Cancer

mTOR (mechanistic Target Of Rapamycin) is a kinase that integrates nutrient, energy, and growth signals to regulate cell growth and proliferation. In cancer:

  • mTOR is hyperactivated in ~70% of cancers through mutations in PI3K, PTEN loss, AKT amplification, or direct mTOR mutations
  • mTOR activation promotes protein synthesis, cell growth, angiogenesis, and metabolic reprogramming
  • mTOR suppression reduces cancer cell proliferation and enhances autophagy (cellular cleanup)
  • Rapamycin inhibits mTORC1, reducing S6K1 and 4E-BP1 phosphorylation, which directly suppresses cancer cell growth

This is why fasting has cancer prevention potential: it naturally suppresses mTOR. Rapamycin does the same thing pharmacologically.

Evidence as a Cancer TREATMENT (Grade A)

Rapamycin analogs are proven cancer drugs:

  • Everolimus (Afinitor): FDA-approved for advanced renal cell carcinoma, breast cancer (HR+/HER2-), neuroendocrine tumors, TSC-associated tumors
  • Temsirolimus (Torisel): FDA-approved for advanced renal cell carcinoma
  • Sirolimus (Rapamune): Used in transplant medicine; post-transplant patients on sirolimus have significantly lower cancer rates than those on other immunosuppressants

The transplant data is particularly telling: kidney transplant recipients on sirolimus have 40-60% lower cancer incidence compared to those on calcineurin inhibitors. This is the closest thing to a "natural experiment" testing rapamycin for cancer prevention.

Evidence as Cancer PREVENTION (Grade C)

Despite the compelling biology and the treatment data, the prevention evidence is limited:

  • No completed RCTs testing low-dose rapamycin for cancer prevention in healthy adults
  • PEARL trial: Evaluating rapamycin for longevity endpoints (may include cancer as secondary)
  • Animal data: Rapamycin extends lifespan and reduces spontaneous tumor incidence in mice (National Institute on Aging Interventions Testing Program, the gold standard for longevity compounds)
  • Epidemiological signal: Transplant registries consistently show lower cancer in rapamycin-treated patients

The Longevity Protocol (Off-Label Use)

Longevity-focused physicians prescribe low-dose rapamycin off-label. The typical protocol:

  • Dose: 3-6mg once weekly (NOT daily as in transplant medicine)
  • Rationale: Weekly dosing inhibits mTORC1 (beneficial) while allowing mTORC2 recovery (avoiding immunosuppression)
  • Cost: $30-100/month depending on source and dose
  • Prescription required: Not available OTC. Longevity clinics, AgelessRx, and some telehealth platforms prescribe it.

Safety at Low Doses

  • At weekly low doses, side effects are generally mild: mouth sores (most common, dose-dependent), mild GI upset
  • Immunosuppression: The main concern. Weekly dosing mitigates this vs. daily dosing, but immune function should be monitored
  • Lipid changes: Can increase triglycerides and cholesterol (monitor lipid panel)
  • Wound healing: May be impaired (pause before/after surgery)
  • NOT recommended during active infections or for immunocompromised individuals

Our Assessment

Rapamycin has the strongest biological rationale for cancer prevention of any prescription drug. mTOR is hyperactivated in most cancers, rapalogs are FDA-approved cancer treatments, and transplant data provides quasi-experimental evidence for prevention. But "compelling biology" is not the same as "proven prevention." We cannot give it a Grade B or higher without human prevention RCT data. For now, it's a reasonable intervention for people already working with a longevity physician who monitors blood work, but it's not something to self-prescribe.

Sources

  • NIA Interventions Testing Program: Rapamycin extends mouse lifespan and reduces tumors
  • NEJM 2009: Everolimus in advanced renal cell carcinoma (RECORD-1)
  • Transplantation: Multiple registry analyses of sirolimus and cancer incidence
  • Nature Reviews Drug Discovery: mTOR in cancer biology and therapy
  • Aging Cell: Rapamycin and healthspan in companion dogs (preliminary)

Related Research

Medical Disclaimer: This is a research review, not medical advice. Always consult with qualified healthcare professionals before making any changes to your health regimen.

How we grade evidence: Grade A = Phase II+ RCT with positive signal. Grade B = Phase I/II or strong epidemiology. Grade C = Preclinical only. Debunked = Retracted or disproven. Full methodology →